Chapter Monthly Meeting & Educational Dinner: Primary HLH and Gamifant
Meat On Ocean
1501 Ocean Avenue
Santa Monica, CA 90401
Wednesday, April 16, 2025 at 6:00pm PT - Wednesday, April 16, 2025 at 9:00pm PT
Add this event to your calendar
Info
Topic
An overview of primary hemophagocytic lymphohistiocytosis (HLH) diagnosis and treatment with Gamifant.
Additional Information
The AACN Chapter at UCLA collaborates with Sobi and other healthcare professionals to bring you a presentation featuring an overview of primary hemophagocytic lymphohistiocytosis (HLH) diagnosis and treatment with Gamifant.
Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.
The session will include an in-depth look at Gamifant as an interferon gamma–blocking antibody treatment option and a Q&A segment for additional information.
Speakers
Clinical Associate Professor, Pediatrics - Stem Cell Transplantation
Member, Maternal & Child Health Research Institute (MCHRI)
Jessica Ann Alexander, MD, describes is a pediatric stem cell transplantation specialist at Stanford Medicine Children’s Health. She uses stem cell transplants to treat immunodeficiency, autoimmunity, immune dysregulation, and bone marrow failure.